兰卫医学
(301060)
| 流通市值：43.29亿 | | | 总市值：48.14亿 |
| 流通股本：3.60亿 | | | 总股本：4.01亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 591,643,227.81 | 287,160,602 | 1,448,033,298.51 | 1,102,095,711.13 |
| 营业收入 | 591,643,227.81 | 287,160,602 | 1,448,033,298.51 | 1,102,095,711.13 |
| 二、营业总成本 | 557,625,336.79 | 271,327,012.7 | 1,426,919,718.5 | 1,065,770,911.06 |
| 营业成本 | 430,506,401.5 | 208,683,324.21 | 1,101,049,071.38 | 835,515,526.13 |
| 税金及附加 | 2,395,650.62 | 1,307,435.64 | 5,752,910.5 | 4,083,362.65 |
| 销售费用 | 31,473,104.47 | 15,257,405.56 | 84,708,443.2 | 59,573,189.24 |
| 管理费用 | 74,840,681.79 | 36,826,056.34 | 193,682,514.22 | 126,048,137.93 |
| 研发费用 | 16,885,789.56 | 8,419,788.78 | 41,052,866.06 | 38,357,166.74 |
| 财务费用 | 1,523,708.85 | 833,002.17 | 673,913.14 | 2,193,528.37 |
| 其中:利息费用 | 2,032,129 | 1,046,355.5 | 6,414,337.38 | 4,839,102.3 |
| 其中:利息收入 | 431,865.91 | 224,757.95 | 6,116,680.71 | 2,994,059.79 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | - | 0 | 51,715.73 | 51,715.73 |
| 加:投资收益 | 3,677,157.79 | 1,655,667.24 | 6,442,536.71 | -767,864.78 |
| 净敞口套期收益 | - | 0 | - | - |
| 资产处置收益 | -182,502.7 | -85,100.26 | -1,265,461.17 | -500,711.14 |
| 资产减值损失(新) | -310,411.82 | -1,356,045.89 | -15,453,256.09 | -3,236,727.51 |
| 信用减值损失(新) | 41,875,148.32 | 25,422,129.9 | -3,749,827.32 | -13,501,833.7 |
| 其他收益 | 6,323,163.96 | 4,761,004.11 | 7,772,455.56 | 6,600,265.04 |
| 四、营业利润 | 85,400,446.57 | 46,231,244.4 | 14,911,743.43 | 24,969,643.71 |
| 加:营业外收入 | 893,192.46 | 178,743.37 | 1,354,421.44 | 942,397.83 |
| 减:营业外支出 | 1,054,411.81 | 448,217.9 | 5,734,859.64 | 4,463,808.51 |
| 五、利润总额 | 85,239,227.22 | 45,961,769.87 | 10,531,305.23 | 21,448,233.03 |
| 减:所得税费用 | 16,686,557.57 | 7,504,761.35 | 25,953,815.54 | 11,240,980.75 |
| 六、净利润 | 68,552,669.65 | 38,457,008.52 | -15,422,510.31 | 10,207,252.28 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 68,552,669.65 | 38,457,008.52 | -15,422,510.31 | 10,207,252.28 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 63,593,763.2 | 36,913,244.73 | -30,746,454.09 | -667,742.31 |
| 少数股东损益 | 4,958,906.45 | 1,543,763.79 | 15,323,943.78 | 10,874,994.59 |
| 扣除非经常损益后的净利润 | 16,392,701.28 | 8,953,863.81 | -44,549,230.61 | -7,537,499.9 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.16 | 0.09 | -0.08 | 0 |
| (二)稀释每股收益 | 0.16 | 0.09 | -0.08 | 0 |
| 九、综合收益总额 | 68,552,669.65 | 38,457,008.52 | -15,422,510.31 | 10,207,252.28 |
| 归属于母公司股东的综合收益总额 | 63,593,763.2 | 36,913,244.73 | -30,746,454.09 | -667,742.31 |
| 归属于少数股东的综合收益总额 | 4,958,906.45 | 1,543,763.79 | 15,323,943.78 | 10,874,994.59 |
| 公告日期 | 2026-08-22 | 2026-04-29 | 2026-04-29 | 2025-10-28 |
| 审计意见(境内) | | | 标准无保留意见 | |